LATS2 and cholangiocarcinoma: For instance, the FDA-approved drug mitomycin C has been shown to upregulate LATS2 expression, induce cellular senescence, and suppress tumor progression in a mouse model of CC, demonstrating the feasibility of restoring this feedback loop pharmacologically (73).